Laurel Wealth Advisors Inc. boosted its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 27.5% during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 13,116 shares of the biopharmaceutical company’s stock after buying an additional 2,828 shares during the period. Laurel Wealth Advisors Inc.’s holdings in Gilead Sciences were worth $929,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in GILD. Tompkins Financial Corp increased its holdings in shares of Gilead Sciences by 4.4% in the second quarter. Tompkins Financial Corp now owns 15,479 shares of the biopharmaceutical company’s stock valued at $1,096,000 after purchasing an additional 651 shares during the period. Benedict Financial Advisors Inc. increased its holdings in shares of Gilead Sciences by 2.7% in the second quarter. Benedict Financial Advisors Inc. now owns 25,473 shares of the biopharmaceutical company’s stock valued at $1,804,000 after purchasing an additional 673 shares during the period. Resource Management LLC increased its holdings in shares of Gilead Sciences by 6.7% in the second quarter. Resource Management LLC now owns 10,688 shares of the biopharmaceutical company’s stock valued at $757,000 after purchasing an additional 674 shares during the period. Jolley Asset Management LLC increased its holdings in shares of Gilead Sciences by 1.3% in the second quarter. Jolley Asset Management LLC now owns 54,746 shares of the biopharmaceutical company’s stock valued at $3,878,000 after purchasing an additional 678 shares during the period. Finally, Kornitzer Capital Management Inc. KS increased its holdings in shares of Gilead Sciences by 0.4% in the second quarter. Kornitzer Capital Management Inc. KS now owns 174,000 shares of the biopharmaceutical company’s stock valued at $12,326,000 after purchasing an additional 710 shares during the period. 77.95% of the stock is currently owned by institutional investors.

Shares of GILD stock opened at $72.78 on Tuesday. Gilead Sciences, Inc. has a 1-year low of $64.27 and a 1-year high of $89.54. The firm has a market cap of $95.13 billion, a P/E ratio of 8.50, a price-to-earnings-growth ratio of -3.73 and a beta of 1.02. The company has a current ratio of 3.00, a quick ratio of 2.92 and a debt-to-equity ratio of 1.23.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings data on Wednesday, July 25th. The biopharmaceutical company reported $1.91 earnings per share for the quarter, topping the Zacks’ consensus estimate of $1.56 by $0.35. The firm had revenue of $5.65 billion for the quarter, compared to analyst estimates of $5.20 billion. Gilead Sciences had a return on equity of 41.57% and a net margin of 9.52%. Gilead Sciences’s quarterly revenue was down 20.9% on a year-over-year basis. During the same quarter in the prior year, the company posted $2.56 earnings per share. equities analysts predict that Gilead Sciences, Inc. will post 6.56 EPS for the current fiscal year.

The company also recently announced a quarterly dividend, which will be paid on Thursday, September 27th. Shareholders of record on Friday, September 14th will be given a dividend of $0.57 per share. The ex-dividend date is Thursday, September 13th. This represents a $2.28 dividend on an annualized basis and a yield of 3.13%. Gilead Sciences’s payout ratio is 26.64%.

A number of research firms have recently issued reports on GILD. Piper Jaffray Companies set a $85.00 target price on Gilead Sciences and gave the company a “buy” rating in a report on Wednesday, September 12th. ValuEngine lowered Gilead Sciences from a “hold” rating to a “sell” rating in a report on Monday, August 20th. BidaskClub lowered Gilead Sciences from a “hold” rating to a “sell” rating in a report on Saturday, August 18th. Mizuho reaffirmed a “buy” rating and set a $94.00 price objective on shares of Gilead Sciences in a report on Friday, August 10th. Finally, Morgan Stanley upped their price objective on Gilead Sciences from $81.00 to $85.00 and gave the stock an “equal weight” rating in a report on Thursday, July 26th. Two analysts have rated the stock with a sell rating, ten have assigned a hold rating, twelve have given a buy rating and two have issued a strong buy rating to the company. The company presently has an average rating of “Buy” and an average price target of $88.30.

In other Gilead Sciences news, Director John C. Martin sold 50,000 shares of the business’s stock in a transaction on Tuesday, September 4th. The stock was sold at an average price of $74.16, for a total transaction of $3,708,000.00. Following the sale, the director now directly owns 3,067,762 shares in the company, valued at $227,505,229.92. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Over the last quarter, insiders have sold 150,000 shares of company stock worth $11,141,000. 1.16% of the stock is owned by company insiders.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, Truvada, Viread, Emtriva, and Tybost for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vosevi, Vemlidy, Epclusa, Harvoni, Sovaldi, Viread, and Hepsera products for treating liver diseases.

See Also: Earnings Per Share (EPS) Explained

Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD).

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.